Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
Approximately 25,000 ovarian cancers are diagnosed in the U.S. annually, and 75% are in the advanced stage and largely incurable. There is critical need for early detection tools and novel treatments. Proteasomal ubiquitin receptor ADRM1 is a protein that is encoded by the ADRM1 gene. Recently, we s...
Main Authors: | Dennis J. Slamon, Richard S. Finn, Gottfried E. Konecny, Michael J. Haykinson, Nuraly K. Avliyakulov, Ondrej Kalous, Erika M. von Euw, Lee Anderson, Marlena S. Fejzo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/14/2/3094 |
Similar Items
-
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
by: Rosie T. Jiang, et al.
Published: (2017-08-01) -
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis
by: Guang-Yang Yu, et al.
Published: (2018-06-01) -
Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
by: Maria Chiara Anania, et al.
Published: (2020-01-01) -
Oncogenes in immune cells as potential therapeutic targets
by: Zakiryanova GK, et al.
Published: (2018-04-01) -
Targeting Oncogenic BRAF: Past, Present, and Future
by: Aubhishek Zaman, et al.
Published: (2019-08-01)